Chimeric antibody for detection and therapy of infectious and inflammatory lesions
CA 2031129 C · Owner: Immunomedics, Inc. · Inventors: Hansen, Hans J.; Goldenberg, David M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A chimeric antibody-agent conjugate for targeting foci of leukocyte accretion comprises a recombinant chimera having an antigen-binding hypervariable region which binds specifically to granulocytes and a constant, region of a human immunoglobulin having an Fc portion with high affinity for receptors on human mononuclear lymphoid cells, said chimera being conjugated to at least one diagnostic agent or therapeutic agent. A method for targeting an imaging or therapy agent to an inflammatory or infectious lesion comprises injecting a mammal parenterally with an effective amount for targeting of the above chimeric anti-leukocyte conjugate.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 4, 1990 and granted April 4, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 4, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 4, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.